Business Context and Reporting Period
Organogenesis Holdings Inc. (ORGO) filed a Form 8-K on November 12, 2024, to announce its financial results for the fiscal third quarter ended September 30, 2024. The filing incorporates a press release as Exhibit 99.1 but does not contain the detailed financial data within the 8-K text itself.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained in the attached press release (Exhibit 99.1), which is not included in the input text.
Material Changes
No material changes versus the prior comparable period are described in the filing text. The document serves solely as a notification that the results have been announced via a separate press release.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, guidance, outlook, risks, contingencies, or details on unusual items. It explicitly states that the information in the attached press release is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific Q3 2024 revenue and earnings figures.
- Verify the company's liquidity position and debt levels as detailed in the full earnings release.
- Check for any forward-looking guidance or updated operational milestones mentioned in the press release.
- Confirm the status of the Class A Common Stock trading on the Nasdaq Capital Market.